Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial

Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Schlumberger, M.; Leboulleux, S.; Catargi, B.; Deandreis, D.; Zerdoud, S.; Bardet, S.; Rusu, D.; Godbert, Y.; Buffet, C.; Schvartz, C.; Vera, P.; Morel, O.; Benisvy, D.; Bournaud, C.; Toubert, M. E.; Kelly, A.; Benhamou, E.; Borget, I.. Lancet Diabetes Endocrinol. 2018; 618-626: p.618-626. doi:10.1016/S2213-8587(18)30113-X
Article